Several clinical studies have suggested that oxidative metabolism of drugs and steroids is disturbed after the therapeutic use of glucocorticoids (Watkins et al., 1985; Watkins et al., 1989) or GH (Levitsky et al., 1989; Cheung et al., 1995; Jurgens et al., 2002) as well as in disease states associated with altered concentrations of circulating hormones. The changes in drug and steroid metabolism observed in these studies suggest that the expression of P450 enzymes may be greatly influenced by extensive and complex hormonal regulation in humans.
With respect to the regulation of CYP genes by glucocorticoid hormones, extensive studies have focused on control by the pregnane X receptor (PXR; NR1I2) as well as the glucocorticoid receptor (GR; NR3C1). For instance, the human CYP3A4 gene, the most abundant P450 isoform in adult livers, could be induced by dexamethasone via a two-step mechanism involving sequential lowand high-concentration components, in which GR and PXR participate in each step, respectively (Pascussi et al., 2000; Pascussi et al., 2001 ).
Female-specific expression of rodent CYP genes, including rat CYP2C12 (MacGeoch et al., 1984; Kamataki et al., 1985) , CYP3A9 (Kawai et al., 2000) and mouse Cyp3a41 (Sakuma et al., 2002) , Cyp3a44 (Sakuma et al., 2002) demonstrated that the sex-specific pattern of growth hormone (GH) secretion from the pituitary gland is a critical determinant of sexually dimorphic expression.
Sex differences in plasma GH profiles are most marked in rodents, but significant male-female differences in the regulation of pituitary GH release also D M D 0 1 9 9 3 5 5 exist in humans (Gatford et al., 1998) . Interestingly, recent experiments using the primary culture of human hepatocytes indicated that the CYP3A4 gene is controlled by GH (Liddle et al., 1998; Dhir et al., 2006) . Additionally, several lines of evidence suggested that the metabolism of several clinical drugs, mainly oxidized by CYP3A4, is more efficient in women than in men (Watkins et al., 1985; Watkins et al., 1989; Greenblatt et al., 1980; Harris et al., 1995; Gorski et al., 1998; Wolbold et al., 2003) . It is therefore interesting whether glucocorticoid-dependent and GH-dependent mechanisms can interact.
Recently, GH-mediated expression of the CYP3A4 gene has been demonstrated to be female-specific in the livers of transgenic mice carrying a BAC clone, which contains the complete CYP3A4 gene sequence, including 5' and 3' flanking regions (Cheung et al., 2006) . Additionally, the expression profile and responsiveness to GH treatment of the human CYP3A4 gene were identical to those of mouse Cyp3a44 gene. These findings strongly suggest that both human CYP3A4 and mouse Cyp3a44 genes share functionally common intrinsic cis-elements, and that these elements function in response to GH signaling in the liver of transgenic mice.
We have previously reported that the mouse Cyp3a41 gene is controlled by GH and glucocorticoid hormones, and that both pathways synergistically interact (Sakuma et al., 2002; Sakuma et al., 2004 (Sakuma et al., 2002) . Their responsiveness to glucocorticoid hormones also differs between the two genes (Bhadhprasit et al., 2007) ; however, it has not been demonstrated whether the expression of the Cyp3a44 gene is synergistically controlled by GH and glucocorticoid hormones, and whether the control mechanism is identical between the two genes.
Therefore, in this report, we investigated the role of GH and glucocorticoid hormones in the regulation of Cyp3a44 gene, and compared it to that of the Cyp3a41 gene. for the first 9 days of life, the pups were subcutaneously injected with MSG at 2 mg/g body weight five times. The pups were weaned at about 28 days of age. GH replacement by rhGH of mice neonatally treated with MSG began at 8 weeks of age. rhGH was administered by either subcutaneous injection at a dose of 50µg/injection twice daily (mimicking male-type GH secretion) or continuous infusion using a subcutaneously implanted micro-osmotic pump at a rate of 1.5
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µg/h (mimicking the female type) for 7 days to male or female mice neonatally treated with MSG, respectively. The effects of MSG treatment were confirmed by verifying growth retardation. GH replacement was checked by examining body weight gain. The mice were sacrified 1 day after the last day of treatment and the liver was excised immediately for preparation of total RNA.
Preparation of primary hepatocyte cultures
The livers of female or male ddY mice were perfused with collagenase-containing Hanks solution and viable hepatocytes were isolated by Percoll isodensity centrifugation as described (Nemoto et al., 1989) . Standard density of 2 x 10 6 cells/ 4 mL/ 60 mm. Waymouth medium did not contain phenol red, a pH indicator, to exclude estrogen-like action. Culture dishes were maintained at 37 °C in a CO 2 -humidified incubator.
Construction of expression plasmids for GR, PXR or RXRα
The GR expression plasmid was generated by replacing the DNA fragment and 5 µl, respectively. Transfection continued for 3 h and then the medium was changed. Cells were treated with DEX at various concentrations and/or GH (71ng/ml) after a further 24 h incubation. Total RNA was prepared from other 24
h-treated cells.
Quantitative RT-PCR analysis
Total RNA was prepared from liver tissues or hepatocytes of mice using TRIzol Gene Expression assay for CYP2D9 (Mm00651731_m1). GAPDH cDNA amplification was detected using TaKaRa RNA PCR Kit (AMV) version 2.1, SYBR Green reagent, and the primer set specific to mouse GAPDH cDNA (Jarukamjorn has not yet been analyzed; therefore, an isoform-specific antibody or substrate is not available at present. Thus, in this report, we investigated the expression of Cyp3a44 and Cyp3a41 genes at mRNA level using real-time RT-PCR, which is able to distinguish the target gene from other highly related but differently controlled genes.
It is known that MSG treatment in the neonatal period produces a profound, but rather selective GH deficiency in adults (Olney and Ho, 1970; Pampori et al., 1991) . Thus, in order to confirm control of the expression of the did not show any effects on expression in male mice. These findings support the idea that GH secretion is a major determinant for the female-specific expression of CYP3A44 mRNA.
In addition to GH, we demonstrated that glucocorticoid hormone also mediates the regulation of Cyp3a44 gene expression in our previous study (Bhadhprasit et al., 2007) . Therefore, to examine synergistic interaction between GH-and glucocorticoid hormone-mediated pathways in vitro, we analyzed the effects of GH and glucocorticoid hormone treatment on the expression of the Cyp3a44 gene using mouse hepatocytes in primary culture, and compared them with those of the Cyp3a41 gene.
As shown in Fig CYP3A41 mRNA, whereas concomitant addition of GH clearly had an inductive effect. Additionally, basal expression and response to these hormone treatments were observed only in cells isolated from female mice, suggesting that intrinsic cellular factor in female hepatocytes might determine the ability to express and respond to these hormones.
It is known that the different secretion pattern of GH is one of the key determinants of the sexually dimorphic expression of several genes; therefore, we examined whether a different profile of GH exposure can cause a distinct response of two genes even with synergistic action with DEX. Primary mouse hepatocytes were exposed to DEX and GH with different protocols for 49 h.
One protocol involved continuous exposure to both hormones, regarded as female type exposure, and the other was discontinuous exposure to GH: hepatocytes were exposed to both GH and DEX for 1 h, and then hepatocytes were exposed to DEX alone for 11h. This successive treatment was repeated for 4 cycles (48 h), and concluded with an additional treatment with GH and DEX for 1 h (total 49 h). We regarded the latter protocol as mimicking male-type secretion. As shown in Fig. 3A , mRNA expression of male-predominant CYP2D9, which is known to be induced by male-type GH secretion (Noshiro exposure to GH, even though cumulative GH exposure during the initial 48 h was the same between the two protocols, and the concentration of GH in the additional final 1h exposure was 12-fold higher than for continuous exposure during the same period (Fig. 3B) .
We have observed a rapid decrease in the expression of presence or absence of GH at 10 -7 M DEX. (Fig. 4B ).
In our previous report, we demonstrated that glucocorticoid-induced expression of the Cyp3a44 gene can be mediated by PXR at supramicromolar concentration (Bhadhprasit et al., 2007) . Thus, we also analyzed the effect of the transfection of expression plasmids for PXR and RXRα. Transfection of mouse PXR (mPXR) and RXRα (mRXRα) expression plasmids enhanced this synergistic interaction on the Cyp3a44 gene approximately 1.9-to 2.7-fold ( 
Discussion
In this study, we examined whether the GH-signaling pathway for Cyp3a44 gene expression interacts with the glucocorticoid signaling pathway.
Experimental data using MSG-treated mice were fundamentally consistent with those of the experiment using hypophysectomized mice (Sakuma et al., 2002) , supporting the idea that GH secretion is one of the major determinants for female-specific expression of CYP3A44 mRNA. Interestingly, continuous administration of GH (1 µg/h) alone into MSG-treated mice clearly induced CYP3A44 expression over the level of untreated female mice, while restoration after the same treatment in hypophysectomized mice was 20% of control female mice (Sakuma et al., 2002) . It is reported that serum glucocorticoid hormone levels declined after hypophysectomy (Pandak et al., 1997) . On the other hand, it was reported that mice neonatally treated with MSG showed increased serum corticosterone levels under resting conditions (Magarinos et al., 1988) . Additionally, when hepatocytes were cultivated in medium containing both DEX and GH, synergistic induction of CYP3A44 mRNA by GH was seen only in cells exposed to GH continuously. Taken together with other data obtained in in vitro experiments, it is possible to predict that interaction between GH signaling by female-type exposure and glucocorticoid hormone signals functions in vivo as well as in vitro, and is involved in female-predominant expression in the liver.
One possible mechanism of female-specific expression is repression by putative male-specific suppressor(s). A highly probable mechanism involves GH This article has not been copyedited and formatted. The final version may differ from this version. pulse-activated STAT5b. It is expected that GH pulse-activated STAT5b could induce the expression of a male-specific repressor, which in turn could inhibit the expression of downstream female-specific genes (Waxman DJ and O'Connor, 2006) . In fact, it is highly likely that the male-specific repression of
Cyp2b9 and Cyp2a4 gene expression in mouse liver is based on this mechanism. In the case of CYP3A44, mRNA expression was not observed in neonatally MSG-treated adult male mice (Fig. 1) , and practically the same observation was made in hypophysectomized male mice (Sakuma et al., 2002) .
This observation supports the idea that female-specific expression of CYP3A44
is not due to repression by masculine GH secretion in males. This hypothesis, based on our studies, agrees with a recent report that CYP3A44 mRNA expression is not induced in STAT5b-deficient mice (Holloway et al., 2006) .
In Fig. 2 , RU-486 alone or the concomitant addition of GH induced CYP3A44 mRNA expression. In contrast, these treatments did not influence CYP3A41 mRNA expression. These different responses to RU486 could be explained by the fact that RU486 has both PXR agonist and GR antagonist activities.
Therefore, CYP3A44 is induced by the PXR agonist activity of RU486 via a PXR-mediated mechanism, while CYP3A41 is not. This explanation is mouse hepatocytes (Fig. 2) . Thus, the participation of this induction mechanism in constitutive expression in the liver was disputable, while involvement in the induction by pharmacological dosing was highly possible. However, the concomitant addition of GH caused strong induction of the expression, suggesting that glucocorticoid signaling participates in constitutive expression by means of cooperative interaction with GH. Based on the result in Fig. 5 , it is predicted that PXR/RXRα could act as a mediator of glucocorticoid signaling at physiological concentration; however, Anakk et al. reported that the expression of CYP3A44 mRNA in female PXR-disrupted mice is unchanged (Anakk et al., 2007) .
Taken together, it is likely that the participation of PXR/RXRα in constitutive expression is partial and can be compensated by GR. Indeed, it is possible for PXR/RXRα to act as a mediator at the pharmacological dose.
In this study, it was revealed that both GR and PXR could be involved in 
